Analysis of the Clinical Efficacy of Buzhong Yiqi Decoction in the Treatment of Mild COVID-19

Abstract

Abstract: Objective: To explore the clinical significance of Buzhong Yiqi decoction in treating patients with mild COVID-19. Methods: 88 patients with mild COVID-19 admitted to the hospital for outpatient treatment from December 2022 to July 2023 were selected as the research subjects. They were divided into two groups through random number generator. The control group was given conventional Western medicine treatment, while the observation group was given Buzhong Yiqi decoction combined treatment. The effects of the two types of treatment were compared and analyzed. Results: Before treatment, there was no difference in inflammatory indicators between the two groups (P > 0.05); after treatment, the C-reactive protein (CRP), white blood cells (WBC), and interleukin-6 (IL-6) levels of the observation group were lower than those of the control group (P < 0.05). The treatment received in the observation group was significantly more effective the treatment received in the control group (P < 0.05). There was no difference in the scores of the traditional Chinese medicine syndrome scale between the two groups before treatment (P > 0.05). The scores for fatigue, sputum, cough, and fever of the observation group after treatment were all lower than those of the control group (P < 0.05). However, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Buzhong Yiqi Decoction can reduce symptoms and improve the body’s inflammatory response of patients with mild COVID-19 patients.